| 第一作者 及年份 | 国家 | 肿瘤类型 | 样本量 | DD临界值 | 年龄 | 治疗方案 | 检测方法 | 结局指标 | NOS评分 |
| Cuicui Zhang 2018 | China | SCLC | 160 | 500 ng/ml | 59 (23 - 83) | chemotherapy | Immunoturbidimetry | PFS | 6 |
| Edyta I. Wolny-Rokicka 2018 | Poland | LC (With metastases) | 95 | 1000 μg/L | 67 (40 - 81) | radiotherapy | ELISA | OS | 9 |
| Edyta I. Wolny-Rokicka 2018 (2) | Poland | LC (Without metastases) | 95 | 1000 μg/L | NA | radiotherapy | ELISA | OS | 9 |
| G. Altiay 2007 | Turkey | LC | 78 | 0.65 μg/ml | 61 (37 - 82) | combine | ELISA | OS | 8 |
| L-P Ge 2015 | China | NSCLC | 82 | 0.55 μg/L | 64 (44 - 72) | chemotherapy | Immunoturbidimetry | PFS | 9 |
| L-R Zhu 2015 (1) | China | LD-SCLC | 74 | 0.55 μg/L | NA | chemotherapy | Immunoturbidimetry | PFS, OS | 7 |
| L-R Zhu 2015 (2) | China | MD-SCLC | 74 | 0.55 μg/L | NA | chemotherapy | Immunoturbidimetry | PFS, OS | 7 |
| Muhammad Abbas 2020 | China | NSCLC | 216 | 0.55 mg/L | 58.29 ± 10.25 | chemotherapy | Microparticle Enzyme Immunoassay | PFS | 8 |
| Shanshan Fan 2019 | China | SCLC | 82 | 0.55 mg/L | 60 (28 - 82) | combine | Immunoturbidimetry | PFS, OS | 8 |
| Wei Xu 2021 | China | NSCLC | 55 | 1000 μg/L | 58 (36 - 77) | radiotherapy | NA | OS | 9 |
| Xuqin Jiang 2017 | China | SCLC | 107 | 0.55 mg/L | 63 (58.5 - 68) | combine | Immunoturbidimetry | OS | 9 |
| Yi Chen 2016 | China | SCLC | 393 | 0.5 μg/mL | 57 (51 - 64) | combine | Immunoturbidimetry | PFS, OS | 8 |
| 田晴文，2019 | 中国 | SCLC | 125 | 1.5 μg/L | 65 | 联合 | NA | PFS | 9 |
| 郑秋青，2014 | 中国 | NSCLC | 135 | 0.551 g/L | 59.5 ± 12.6 | 化疗 | NA | PFS, OS | 9 |